Clinical trials: Empagliflozin
Coronary Artery Disease, Type 2 Diabetes
Empagliflozin Versus Vildagliptin in CAD Patients With T2DM
We compared the cardioprotective effects of empagliflozin, an SGLT2 inhibitor, with those of vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, focusing on various inflammatory biomarkers lipid profile, and cardiac…
- Trial name
- NCT06313008
- Testing
- Empagliflozin 10 MG, Vildagliptin 50 MG
- Where
- Egypt
- Volunteers
- 120 people
- Sponsor
- Damanhour University
HFpEF, LVDD
Triple Combination Therapy (ARNI, SGLT2i, MRA) in Advanced HFpEF
Patients with advanced heart failure with preserved ejection fraction (HFpEF) will be randomly assigned in open-label multicenter study to receive triple combination therapy with [angiotensin receptor/neprilysin inhibitor [ARNI]…
- Conditions
- HFpEF, LVDD, Myocardial Fibrosis
- Trial name
- NCT06655480
- Testing
- [ARNI + SGLTi + AMR], [SGLTi + previously taken RAAS blocker]
- Where
- Russia
- Volunteers
- 50 people
- Sponsor
- National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Diabete Mellitus
The Efficacy and Safety of Empagliflozin - Linagliptin and Empagliflozin- Metformin Therapy in Reduction of Body Weight in Type 2 Diabetic Patients .
The goal of this clinical trial is - Comparison of Empagliflozin - Linagliptin with Empagliflozin - Metformin combination therapy in reduction of body weight in T2DM Patients and it included 200 diabetic subjects with total study…
- Trial name
- NCT07247656
- Testing
- (Empagliflozin 10 mg+ Tab Linagliptin 5mg), Tab Empagliflozin 10 mg + Tab Metformin 500 mg
- Where
- Pakistan
- Volunteers
- 200 people
- Sponsor
- Bahria University
Type 2 Diabetes Mellitus, Nonalcoholic Fatty Liver Disease
Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
This prospective, open-label, randomized clinical study will evaluate the effect of empagliflozin 10 mg daily, added to standard T2DM treatment, on liver fat and hepatic parameters in adults with type 2 diabetes and nonalcoholic…
- Trial name
- EMPA-LIVER (NCT07915596)
- Testing
- Empagliflozin 10/15 mg administered orally once daily in addition to standard treatment for type 2 diabetes mellitus.
- Where
- Bangladesh
- Volunteers
- 792 people, healthy volunteers welcome
- Sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Heart Failure, Reduced Ejection Fraction Heart Failure
Sodium-glucose Transport 2 Inhibitors (SGLT2i) in HFrEF Patients
The aim of this study is to assess the efficacy, safety and cardiovascular outcomes of Sodium-glucose transport protein 2 inhibitors (SGLT2i) therapy in patients with heart failure reduced ejection fraction ( HFrEF) with and…
- Trial name
- NCT06065280
- Testing
- Empagliflozin 10 MG, Dapagliflozin 10 MG
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Damanhour University
Heart Failure Acute, Heart Failure，Congestive
Effects of Empagliflozin on Clinical Outcomes in Patients With Acute Decompensated Heart Failure
Acute decompensated heart failure is the fastest growing disease in the world and the leading cause of hospital admissions worldwide.
- Conditions
- Heart Failure Acute, Heart Failure，Congestive, Heart Failure; With Decompensation
- Trial name
- EMPA-RESPONSE (NCT03200860)
- Testing
- Empagliflozin 10 MG
- Where
- 5 sites in Netherlands
- Volunteers
- 80 people
- Sponsor
- University Medical Center Groningen
Hematocrit Change, Cardiovascular Prevention
Empagliflozin and Red Blood Cell 2,3-biphosphoglycerate Levels
The aim of this study is to investigate the hypothesis that treatment with empagliflozin may have an impact on red blood cell 2,3-biphosphoglycerate levels affecting tissue oxygen supply and thus mediating part of the cardio- and…
- Conditions
- Hematocrit Change, Cardiovascular Prevention, Empagliflozin, SGLT2-Inhibitors
- Trial name
- NCT06284850
- Testing
- Empagliflozin10Mg Tab
- Where
- Greece
- Volunteers
- 40 people
- Sponsor
- Aristotle University Of Thessaloniki
Diabetes Mellitus, Type 2
BI 10773 add-on to Metformin in Patients With Type 2 Diabetes
The objective of the current study is to investigate the efficacy, safety and pharmacokinetics of five doses of BI 10773 compared to placebo given for 12 weeks as add-on therapy to on going metformin therapy in patients with T2DM…
- Trial name
- NCT00749190
- Testing
- BI 10773, sitagliptin
- Where
- 116 sites in United States, Argentina and 14 more
- Volunteers
- 495 people
- Sponsor
- Boehringer Ingelheim
Hypertension, Type II Diabetes
Double Blind Placebo Study of JARDIANCE® (Empagliflozin) in Prehypertensives Type II Diabetics
Objectives: Primary 1. Primary prevention of new onset of hypertension Secondary 1. Reduction of 24h BP in type II diabetics with prehypertension 2.
- Trial name
- PREHYPD (NCT01001962)
- Testing
- empagliflozin, Metformin
- Where
- Greece
- Volunteers
- 1,054 people
- Sponsor
- Aristotle University Of Thessaloniki
Type 2 Diabetes
Metformin Hydrochloride and Empagliflozin Tablets in the Treatment of Type 2 Diabetes
The main objective of this study is to evaluate the efficacy and safety of Metformin Hydrochloride and Empagliflozin Tablets in the treatment of type 2 diabetes in real-world clinical settings.
- Trial name
- NCT07003191
- Testing
- Metformin Hydrochloride and Empagliflozin tables (Fixed-Dose Combination)
- Where
- China
- Volunteers
- 2,600 people
- Sponsor
- Sun Yat-sen University
Healthy
BI 10773 Administered as Oral Solution to Healthy Male Volunteers
Study to determine the pharmacokinetics of BI 10773 and total radioactivity including excretion mass balance, excretion pathways and metabolism following the oral administration of [14C] BI 10773
- Trial name
- NCT02172274
- Testing
- [14C]-BI 10773 - oral solution
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Non-Alcoholic Fatty Liver Disease
Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease
This study is a randomized, double-blind, placebo-controlled trial specifically designed to evaluate the preliminary feasibility, initial efficacy and safety of SGLT2 inhibitors for treating NAFLD in adolescents with obesity.
- Trial name
- SHIELD (NCT06355310)
- Testing
- Empagliflozin 10 MG
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Justin Ryder
Type 2 Diabetes
Variable Effects of Anti-diabetics on Stress Hyperglycemia Ratio
A blood glucose level of equal to or greater than 180 mg/dL that occurred during stress in a patient without diabetes mellitus (DM) is termed stress hyperglycemia (SH).
- Trial name
- NCT05822674
- Testing
- Sitagliptin/metformin ( 50/500mg) Oral Tablet, Empagliflozin/metformin(10/500mg) Oral Tablet
- Where
- Iraq
- Volunteers
- 80 people
- Sponsor
- University of Diyala
Diabetes Mellitus, Type 2
A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy
The aim of this study is to investigate the efficacy and safety of two doses (high and low) of empagliflozin as add-on therapy to metformin in patients with type 2 diabetes mellitus (T2DM) and insufficient glycaemic control.
- Trial name
- NCT01649297
- Testing
- empagliflozin (low dose qd), Empagliflozin (high dose qd), empagliflozin (high dose bid)
- Where
- 139 sites in United States, Australia and 16 more
- Volunteers
- 983 people
- Sponsor
- Boehringer Ingelheim
Obesity, Weight Loss
Mechanistic Insights to Weight Loss Maintenance Through SGLT2 Inhibitors
Obesity increases the risk of cardiometabolic diseases such as hypertension and diabetes. Weight loss interventions such as low-calorie diet and physical activity are effective for weight loss in the short term, but weight loss…
- Trial name
- NCT05885074
- Testing
- Empagliflozin Arm, Control Arm, Exercise capacity VO2 maximum determination
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Non-alcoholic Fatty Liver Disease
Effect of Empagliflozin on Liver Fat in Non-diabetic Patients
Non-alcoholic fatty liver disease (NAFLD) is a global epidemic with a prevalence of 25%. Currently therapies for NAFLD patients without diabetes mellitus (DM) are limited, and are associated with various adverse side effects.
- Trial name
- NCT04642261
- Testing
- Empagliflozin 10 MG
- Where
- Hong Kong
- Volunteers
- 98 people
- Sponsor
- The University of Hong Kong
Kidney Disease, Chronic
A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease
This study is open to adults with chronic kidney disease. People with and without type 2 diabetes can take part in this study. The purpose of this study is to find out whether a medicine called BI 690517 improves kidney function…
- Trial name
- NCT05182840
- Testing
- BI 690517, Empagliflozin
- Where
- 203 sites in United States, Argentina and 27 more
- Volunteers
- 714 people
- Sponsor
- Boehringer Ingelheim
Myocardial Suppression
Suppression With Empagliflozin as an Alternative To High-Fat Low-Carbohydrate Diet for Myocardial F-fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Imaging
The overall objective of this study is to assess if the empagliflozin has the potential to substitute the high fat low carb (HFLC) diet for the preparation of cardiovascular FDG-PET studies.
- Trial name
- SWEET-HEART (NCT06350903)
- Testing
- Fast + High-fat low-carbohydrate diet, Fast + Empagliflozin
- Where
- Canada
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Matthieu Pelletier-Galarneau, MD MSc
Diabetes Mellitus, Type 2, Cardiovascular Diseases
A Prospective Trial of Enavogliflozin to Evaluate Cardio-renal Outcome in Type 2 Diabetes Mellitus Patients
The novel sodium-glucose cotransporter-2 (SGLT2) inhibitor, enavogliflozin, effectively reduces glycated hemoglobin (HbA1c) levels and body weight without increasing the risk of serious adverse events.
- Conditions
- Diabetes Mellitus, Type 2, Cardiovascular Diseases, Kidney Diseases
- Trial name
- ENVELOP (NCT06642623)
- Testing
- Enavogliflozin, Dapagliflozin or Empagliflozin
- Where
- South Korea
- Volunteers
- 2,862 people
- Sponsor
- Yonsei University
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN Study
This is a randomized, double-blind, double-dummy, placebo-controlled, cross over design trial with empagliflozin compared to placebo that is added to open-label ramipril.
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Obesity
- Trial name
- NCT02632747
- Testing
- Empagliflozin, ramipril
- Where
- Canada
- Volunteers
- 31 people
- Sponsor
- Boehringer Ingelheim